Genistein, a competitive PDE1-4 inhibitor, may bind on high-affinity rolipram binding sites of brain cell membranes and then induce gastrointestinal adverse effects

European Journal of Pharmacology

Volumn 643, Issue 1, 2010, Pages 113-120

  Shih, Chung Hong ^a   Lin, Ling Hung ^a   Lai, Ya Hsin ^b   Lai, Chi Yin ^b   Han, Cheng Ying ^b   Chen, Chien Ming ^b   Ko, Wun Chang ^a,b  

^a TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Allergic asthma; Cytokine; Gastrointestinal adverse effect; Genistein; High affinity rolipram binding site; Phosphodiesterase isozymes 1 4 inhibition

Indexed keywords

GAMMA INTERFERON; GENISTEIN; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; KETAMINE; METHACHOLINE; OVALBUMIN; PHOSPHODIESTERASE I; PHOSPHODIESTERASE III; PHOSPHODIESTERASE IV; ROLIPRAM; SPLEEN EXONUCLEASE; TUMOR NECROSIS FACTOR ALPHA; XYLAZINE;

ALLERGIC ASTHMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BINDING AFFINITY; BRAIN CELL; CELL MEMBRANE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG BINDING SITE; DRUG PROTEIN BINDING; EOSINOPHIL COUNT; FEMALE; GASTROINTESTINAL SYMPTOM; HEART; INFLAMMATORY CELL; INHIBITION KINETICS; LUNG LAVAGE; LUNG PARENCHYMA; LYMPHOCYTE COUNT; MACROPHAGE; MOUSE; NEUTROPHIL COUNT; NONHUMAN; PRIORITY JOURNAL; TISSUE HOMOGENATE; TOXICITY TESTING; TREATMENT DURATION;

EID: 77955085786     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.06.026     Document Type: Article

References (51)

1. Ahn H.S., Crim W., Romano M., Sybertz E., Pitts B. Effects of selective inhibitors on cyclic nucleotide phosphodiesterases of rabbit aorta. Biochem. Pharmacol. 1989, 38:3331-3339.
2. Akiyama T., Ishida J., Nakagawa S., Ogawara H., Watanabe S.I., Itoh N., Shibuya M., Fukami Y. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J. Biol. Chem. 1987, 262:5592-5595.
3. 3H]rolipram binding. Biochem. Pharmacol. 1996, 51:949-956.
4. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72:248-254.
5. Busse W.W., Lemanske R.F. Asthma. N. Engl. J. Med. 2001, 344:350-362.
6. 3H]-rolipram binding in guinea pig tissues. Investig. New Drugs 2008, 26:417-424.
7. - secretion via phosphodiesterase modulation in the mouse jejunum. Am. J. Physiol. Cell Physiol. 2009, 297:C688-C698.
8. de Boer J., Philpott A.J., van Amsterdam R.G., Shahid M., Zaagsma J., Nicholson C.D. Human bronchial cyclic nucleotide phosphodiesterase isoenzymes: biochemical and pharmacological analysis using selective inhibitors. Br. J. Pharmacol. 1992, 106:1028-1034.
9. Draheim R., Egerland U., Rundfeldt C. Anti-inflammatory potential of the selective phosphodiesterase 4 inhibitor N-(3, 5-dichloro-pyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl]-glyoxy lic acid amide (AWD 12-281), in human cell preparations. J. Pharmacol. Exp. Ther. 2004, 308:555-563.
10. Duan W., Kuo I.C., Selvarajan S., Chua K.Y., Bay B.H., Wong W.S. Antiinflammatory effects of genistein, a tyrosine kinase inhibitor, on a guinea pig model of asthma. Am. J. Respir. Crit. Care Med. 2003, 167:185-192.
11. Formica J.V., Regelson W. Review of the biology of quercetin and related bioflavonoids. Food Chem. Toxicol. 1995, 33:1061-1080.
12. Fotsis T., Pepper M.S., Aktas E., Breit S., Rasku S., Adlercreutz H., Wahala K., Montesano R., Schweigerer L. Flavonoids, dietary-derived inhibitors of cell proliferation and in vitro angiogenesis. Cancer Res. 1997, 57:2916-2921.
13. Giembycz M.A. Phosphodiesterase 4 inhibitors and the treatment of asthma: where are we now and where do we go from here?. Drugs 2000, 59:193-212.
14. Giembycz M.A. Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking?. Br. J. Pharmacol. 2008, 155:288-290.
15. Hamelmann E., Schwarze J., Takeda K., Oshiba A., Larsen G.L., Irvin C.G., Gelfand E.W. Noninvasive measurement of airway responsiveness in allergic mice using barometric plethysmography. Am. J. Respir. Crit. Care Med. 1997, 156:766-775.
16. Harrison S.A., Reifsnyder D.H., Gallis B., Cadd G.G., Beavo J.A. Isolation and characterization of bovine cardiac muscle cGMP-inhibited phosphodiesterase: a receptor for new cardiotonic drugs. Mol. Pharmacol. 1986, 29:506-514.
17. Hatzelmann A., Schudt C. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J. Pharmacol. Exp. Ther. 2001, 297:267-279.
18. Illek B., Fischer H., Santos G.F., Widdicombe J.H., Machen T.E., Reenstra W.W. cAMP-independent activation of CFTR Cl channels by the tyrosine kinase inhibitor genistein. Am. J. Physiol. 1995, 268:C886-C893.
19. Janssen L.J., Lu-Chao H., Netherton S. Responsiveness of canine bronchial vasculature to excitatory stimuli and to cooling. Am. J. Physiol. Lung Cell. Mol. Physiol. 2001, 280:L930-L937.
20. Janssen L.J., Wattie J., Lu-Chao H., Tazzeo T. Muscarinic excitation-contraction coupling mechanisms in tracheal and bronchial smooth muscles. J. Appl. Physiol. 2001, 91:1142-1151.
21. Kanehiro A., Ikemura T., Makela M.J., Lahn M., Joetham A., Dakhama A., Gelfand E.W. Inhibition of phosphodiesterase 4 attenuates airway hyperresponsiveness and airway inflammation in a model of secondary allergen challenge. Am. J. Respir. Crit. Care Med. 2001, 163:173-184.
22. Kim E., Chun H.O., Jung S.H., Kim J.H., Lee J.M., Suh B.C., Xiang M.X., Rhee C.K. Improvement of therapeutic index of phosphodiesterase type IV inhibitors as anti-asthmatics. Bioorg. Med. Chem. Lett. 2003, 13:2355-2358.
23. Ko W.C., Chen M.C., Wang S.H., Lai Y.H., Chen J.H., Lin C.N. 3-O-methylquercetin more selectively inhibits phosphodiesterase subtype 3. Planta Med. 2003, 69:310-315.
24. Ko W.C., Shih C.M., Lai Y.H., Chen J.H., Huang H.L. Inhibitory effects of flavonoids on phosphodiesterase isozymes from guinea pig and their structure-activity relationships. Biochem. Pharmacol. 2004, 68:2087-2094.
25. Lee M.E., Markowitz J., Lee J.O., Lee H. Crystal structure of phosphodiesterase 4D and inhibitor complex (1). FEBS Lett. 2002, 530:53-58.
26. Lin C.C., Chen J.L., Ko W.C. Relaxation of isolated guinea pig trachea by genistein via inhibition of phosphodiesterase. Planta Med. 2007, 73:323-329.
27. Lipworth B.J. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet 2005, 365:167-175.
28. Marini H., Minutoli L., Polito F., Bitto A., Altavilla D., Atteritano M., Gaudio A., Mazzaferro S., Frisina A., Frisina N., Lubrano C., Bonaiuto M., D'Anna R., Cannata M.L., Corrado F., Adamo E.B., Wilson S., Squadrito F. Effects of the phytoestrogen genistein on bone metabolism in osteopenic postmenopausal women: a randomized trial. Ann. Intern. Med. 2007, 146:839-847.
29. Murphy A.W., Platts-Mills T.A.E. Drug used in asthma and obstructive lung disease. Human Pharmacology-Molecular to Clinical 1998, 797-809. Mosby, St. Louis, MO. T.M. Brody, J. Larner, K.P. Minneman (Eds.).
30. Nichols M.R., Morimoto B.H. Tyrosine kinase-independent inhibition of cyclic-AMP phosphodiesterase by genistein and tyrphostin 51. Arch. Biochem. Biophys. 1999, 366:224-230.
31. O'Connell J.C., McCallum J.F., McPhee I., Wakefield J., Houslay E.S., Wishart W., Bolger G., Frame M., Houslay M.D. The SH3 domain of Src tyrosyl protein kinase interacts with the N-terminal splice region of the PDE4A cAMP-specific phosphodiesterase RPDE-6 (RNPDE4A5). Biochem. J. 1996, 318(Pt 1):255-261.
32. Pages L., Gavalda A., Lehner M.D. PDE4 inhibitors: a review of current developments (2005-2009). Expert Opin. Ther. Pat. 2009, 19:1501-1519.
33. Podzuweit T., Nennstiel P., Muller A. Isozyme selective inhibition of cGMP-stimulated cyclic nucleotide phosphodiesterases by erythro-9-(2-hydroxy-3-nonyl) adenine. Cell. Signal. 1995, 7:733-738.
34. Reeves M.L., Leigh B.K., England P.J. The identification of a new cyclic nucleotide phosphodiesterase activity in human and guinea-pig cardiac ventricle. Implications for the mechanism of action of selective phosphodiesterase inhibitors. Biochem. J. 1987, 241:535-541.
35. Revets H., Pynaert G., Grooten J., De Baetselier P. Lipoprotein I, a TLR2/4 ligand modulates Th2-driven allergic immune responses. J. Immunol. 2005, 174:1097-1103.
36. Robichaud A., Savoie C., Stamatiou P.B., Tattersall F.D., Chan C.C. PDE4 inhibitors induce emesis in ferrets via a noradrenergic pathway. Neuropharmacology 2001, 40:262-269.
37. Robichaud A., Savoie C., Stamatiou P.B., Lachance N., Jolicoeur P., Rasori R., Chan C.C. Assessing the emetic potential of PDE4 inhibitors in rats. Br. J. Pharmacol. 2002, 135:113-118.
38. 2-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis. J. Clin. Invest. 2002, 110:1045-1052.
39. Schneider H.H., Schmiechen R., Brezinski M., Seidler J. Stereospecific binding of the antidepressant rolipram to brain protein structures. Eur. J. Pharmacol. 1986, 127:105-115.
40. Silver P.J., Hamel L.T., Perrone M.H., Bentley R.G., Bushover C.R., Evans D.B. Differential pharmacologic sensitivity of cyclic nucleotide phosphodiesterase isozymes isolated from cardiac muscle, arterial and airway smooth muscle. Eur. J. Pharmacol. 1988, 150:85-94.
41. Smith L.J., Holbrook J.T., Wise R., Blumenthal M., Dozor A.J., Mastronarde J., Williams L. Dietary intake of soy genistein is associated with lung function in patients with asthma. J. Asthma 2004, 41:833-843.
42. Stringfield T.M., Morimoto B.H. Modulation of cyclic AMP levels in a clonal neural cell line by inhibitors of tyrosine phosphorylation. Biochem. Pharmacol. 1997, 53:1271-1278.
43. Thompson W.J., Appleman M.M. Multiple cyclic nucleotide phosphodiesterase activities from rat brain. Biochemistry 1971, 10:311-316.
44. Tsang F., Wong W.S.F. Inhibitors of tyrosine kinase signaling cascade attenuated antigen challenge of guinea-pig airways in vitro. Am. J. Respir. Crit. Care Med. 2000, 162:126-133.
45. Ueki H., Mitsugi S., Kawashima Y., Motoyashiki T., Morita T. Orthovanadate stimulates cyclic guanosine monophosphate-inhibited cyclic adenosine monophosphate phosphodiesterase activity in isolated rat fat pads through activation of particulate myelin basic protein kinase by protein tyrosine kinase. Endocrinology 1997, 138:2784-2789.
46. Underwood D.C., Kotzer C.J., Bochnowicz S., Osborn R.R., Luttmann M.A., Hay D.W., Torphy T.J. Comparison of phosphodiesterase III, IV and dual III/IV inhibitors on bronchospasm and pulmonary eosinophil influx in guinea pigs. J. Pharmacol. Exp. Ther. 1994, 270:250-259.
47. Vojdani A., Erde J. Regulatory T cells, a potent immunoregulatory target for CAM researchers: the ultimate antagonist (I). Evid. Based Complement. Altern. Med. 2006, 3:25-30.
48. Wang H.K., Xia Y., Yang Z.Y., Natschke S.L., Lee K.H. Recent advances in the discovery and development of flavonoids and their analogues as antitumor and anti-HIV agents. Adv. Exp. Med. Biol. 1998, 439:191-225.
49. Winterrowd G.E., Chin J.E. Flow cytometric detection of antigen-specific cytokine responses in lung T cells in a murine model of pulmonary inflammation. J. Immunol. Meth. 1999, 226:105-118.
50. 3H]-rolipram from high-affinity rolipram binding sites and reversed xylazine/ketamine-induced anesthesia. Eur. J. Pharmacol. 2010, 627:269-275.
51. 3H]rolipram. J. Pharmacol. Exp. Ther. 2003, 305:565-572.